U.S. DOD CDMRP - Peer Reviewed Alzheimer’s Disease Research Program

Thumbnail

Event details

Date 17.06.2022  
Category Call for proposal

Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Peer Reviewed Alzheimer’s Disease Research Program (PRARP). Three award programs are available:

  • The Translational Research Award support translational research that will accelerate the movement of promising products and knowledge in Alzheimer’s disease (AD) / AD-related dementias (ADRD) research into clinical applications, including healthcare products and interventions, technologies, behavioral modalities, social modalities, and/or clinical practice guidelines. This mechanism supports both preclinical-to-clinical translational research (e.g., studies of interventions and medical devices in preclinical systems) and clinical research-to-clinical care translation (e.g., comparative effectiveness, implementation science, healthcare services research).
     
  • The FY22 Investigator- Initiated Research Award supports studies that will make important contributions to TBI and/or military-service-related factors as they pertain to AD/ADRD research, patient care, and quality of life. The work should innovatively challenge existing paradigms or exhibit high levels of creativity. Applications may focus on any phase of research from basic through translational. The program encourages applications that include meaningful and productive collaborations between investigators.
     
  • The FY22 Accelerating Diagnostics Research Award support high-impact advancement of robust diagnostic and/or prognostic factors pertaining to AD/ADRD following military service and/or TBI. Applications meeting the intent of this mechanism will accelerate clinically useful factors for rapid transfer to clinical practice to bridge a critical gap between identification of relevant factors and clinical usage. The proposed factors for investigation must correlate with clinical endpoints relevant to AD/ADRD following military service and/or traumatic brain injury.

AREAS OF INTEREST
To address the intent of the award mechanism, applications submitted to this program announcement must address at least one of the Focus Areas:
  • Individual, caregiver, and family support:
  • Diagnostic, environmental, and prognostic factors
  • Foundational science to improve understanding of the mechanisms, etiology, comorbidities, therapeutics/treatments

DEADLINE:
  • FY22 Translational Research Award - Pre-Application (1 page limit): June 17, 2022, submission on July 25, 2022
  • FY22 Investigator- Initiated Research Award - Pre-Application (1 page limit): June 17, 2022, submission on July 25, 2022
  • FY22 Accelerating Diagnostics Research Award - Pre-Application (1 page limit): June 17, 2022, submission on July 25, 2022

FUNDING:
  • FY22 Translational Research Award - Anticipated total costs will not exceed $1.2M for a maximum of 4 years period of performance
  • FY22 Investigator- Initiated Research Award - Anticipated total costs will not exceed $750,000 for 3 years period of performance
  • FY22 Accelerating Diagnostics Research Award - Anticipated total costs will not exceed $2.5M for 4 years period of performance

ELIGIBILITY: EPFL researchers are eligible to participate.

HOW TO APPLY: Pre-applications are submitted through the eBRAP platform. Full applications will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.

FOR FURTHER INFORMATION: Please refer to the FOAs below and feel free to contact the Research Office for any question or any help.

Practical information

  • General public
  • Free

Contact

Event broadcasted in

Share